Alumis Inc. Common Stock

NASDAQ:ALMS

Biotechnology

Healthcare
$4.40 +0.91%

+$0.21 today

Market cap
$568.87M
Beta
-0.54
P/E (TTM)
-12.2
EPS (TTM)
-$1.90
52W Low $2.76High $30.60

Volume 2.01M

Average 1.31M

ALMS Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Alumis Inc. Common StockNASDAQ: ALMS

Accounts Payables · Q2 FY2026 · quarter ended Jun 2026

Accounts payables grows, but more slowly than its trailing trend

Q2 FY2026 accounts payables of $1.26M rose 27.6% year over year, behind the +391.0% change in trailing-twelve-month accounts payables. Sequentially, it fell 11.9% from the prior quarter.

Context

  • Accounts payables amounted to 25.1% of revenue in FY2025.
  • Accounts payables increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +27.6% toward the trailing-twelve-month pace of +391.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$1.26M-11.9% QoQ
Last fiscal yearDec 2025
-$6.04M-171.0% YoY
LTMJun 2026
-$2.18M+391.0% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+27.6%——
1 year-171.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
(6.04M) USD
Year-over-year change
-171.0%

Accounts Payables vs competitors

How ALMS compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +391.0% is the 2nd highest of 7, against a peer median of +82.0%.
  • Accounts payables amounts to 29.5% of revenue for ALMS, versus a peer median of 99.2%.
ALMS Competitors
Accounts Payables for ALMS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ANABAnaptysBio, Inc.LTM Mar 2026$81.11M USD+53.9%—34.9%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$8.3M USD+286.2%+184.2%99.2%
IFRXInflaRx N.V.LTM Mar 2026€6.32M EUR—+17.8%21552.6%
ALMSAlumis Inc. Common StockLTM Jun 2026$2.18M USD+391.0%—29.5%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$1.01M USD+447.4%——
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$532K USD+110.0%+0.6%0.2%
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$325K USD+38.3%-33.1%550.8%
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$204.79K USD-411.0%-70.8%—
TLSATiziana Life Sciences LtdFY2025$0 USD———
ODTXOdyssey Therapeutics, Inc.—— ———
AGMBAgomAb Therapeutics N.V. American Depositary Shares—— ———
Peer median (excluding ALMS) —+82.0%+0.6%99.2%

Competitors are the stored peer set for ALMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(111.93M)(154.99M)(294.23M)(243.33M)
Depreciation & Amortization250K1.28M3.15M3.5M
Deferred Income Tax000(8.56M)
Stock-Based Compensation5.96M8.63M19.46M43.52M
Change in Working Capital(1.92M)12.06M14.76M26.32M
Accounts Receivables0000
Inventory0000
Accounts Payables1.29M(642K)8.51M(6.04M)
Other Working Capital(3.21M)12.7M6.25M32.35M
Other Non-Cash Items(86K)3.05M1.79M(190.98M)
Operating Cash Flow(107.72M)(129.98M)(255.08M)(369.52M)
Capital Expenditures(2.41M)(4.5M)(1.73M)(653K)
Acquisitions (Net)0000
Purchases of Investments(209.08M)(11.28M)(240.06M)(209.17M)
Sales of Investments142.73M76.25M128M447.96M
Other Investing Activities00049.74M
Investing Cash Flow(68.75M)60.47M(113.79M)287.88M
Debt Repayment0000
Common Stock Issued00193.32M2.08M
Common Stock Repurchased000(17K)
Dividends Paid0000
Other Financing Activities1.73M(96K)40.59M0
Financing Cash Flow101.63M89.68M492.37M2.07M
Effect of Forex Changes0000
Net Change in Cash(74.85M)20.18M123.5M(79.58M)
Free Cash Flow(110.13M)(134.47M)(256.81M)(370.18M)

Alumis Inc. Common Stock

NASDAQ:ALMS

Intrinsic Alpha fair value

Locked

Current Price

$4.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.